Late onset Friedreich’s disease: clinical features and mapping of mutation to the FRDA locus

G De Michele, A Filla, F Cavalcanti, L Di Maio, L Pianese, I Castaldo, O Calabrese, A Monticelli, S Varrone, G Campanella, M Leone, M Pandolfo, S Cocozza

Abstract

Twenty two patients from 17 families with Friedreich’s disease phenotype but with onset ranging from the ages of 21 to 36 are described. Comparison with “typical” Friedreich’s disease with onset before 20 years of age showed only a lower occurrence of skeletal deformities. The peripheral and central neurophysiological findings, sural nerve biopsy, and the neuroradiological picture did not allow the differentiation between “late onset” and “typical” Friedreich’s disease. Duration of disease from onset to becoming confined to a wheelchair was five years longer in late onset patients. Sixteen patients and 25 healthy members from eight families were typed with the chromosome 9 markers MLS1, MS, and GS4 tightly linked to the FRDA locus. All families showed positive lod scores with a combined value of 5.17 at a recombination fraction of θ = 0.00. It is concluded that “late onset” Friedreich’s disease is milder than the “typical” form and it maps to the same locus on chromosome 9.

Friedreich’s disease is an autosomal recessive disorder that represents the most common form of hereditary ataxia in large series. Age of onset was at about the time of puberty in the nine patients originally described by Friedreich, but a later onset has sometimes been described. For instance, Potts reported an onset between ages 27 and 36 years in three siblings. Geoffroy et al., in an effort to define strict diagnostic criteria for Friedreich’s disease, established that “true” Friedreich’s disease must always begin before the end of puberty and at the latest before the age of 20. Harding considered the onset before 25 years of age an essential diagnostic criterion.

In 1989 we reported nine patients with Friedreich’s disease phenotype but with age of onset ranging from 21 to 29. We suggested that “late onset” Friedreich’s disease may be a distinct genetic entity or may result from modifying secondary genes in some families. Chamberlain et al. mapped the Friedreich’s disease gene (FRDA) on the centromeric region of chromosome 9, without evidence of genetic heterogeneity. The original findings have been confirmed in large studies on “typical” Friedreich’s disease from European and North American populations. Klockgether et al., with markers of the FRDA region, found identical genotypes in three affected members of one family with late onset Friedreich’s disease, but not in two unaffected siblings.

Here we report the results of an expanded clinical and laboratory study and of a molecular genetic analysis in late onset Friedreich’s disease. The aim of the study was to clarify whether it represents a distinct entity, clinically and genetically different from “typical” Friedreich’s disease.

Patients and methods

At the Department of Neurology of the Federico II University of Naples, we saw 114 patients from southern and central Italy who fulfilled the following diagnostic criteria for Friedreich’s disease: autosomal recessive inheritance or sporadic occurrence, progressive ataxia of limbs and gait, and absence of knee and ankle jerks. At least one of the following signs was present in the index cases: dysarthria, extensor plantar response, and echocardiographic evidence of hypertrophic cardiomyopathy. Fifty nine of them had onset by 20 years of age and received the diagnosis of Friedreich’s disease. The present study concerns the 19 patients whose onset age was older than 20 and three similar patients from northern Italy (referred by MP and ML).

Severity of disease was scored according to the Inherited Ataxia Progression Scale (IAPS): stage 1, asymptomatic affected sibling; stage 2, symptoms present but mild; stage 3, patient needs constant care and cannot work; stage 4, patient confined to a wheelchair.

The following microsatellite polymorphisms were studied for linkage analysis: GS4 (D9S111), MCT112/MS (D9S15), MLS1 (D9S202), 13 For the DNA analysis a blood sample was taken in 50 mM EDTA. Genomic DNAs were prepared according to described procedures. The polymerase chain reaction was used to detect microsatellite polymorphisms. DNA from each subject was amplified in 50 µl of polymerase chain reaction buffer (10 mM Tris HCl pH 8.3, 1-5
mM MgCl₂, 50 mM KCl, 0.001% gelatine) containing 10 pmol of 32P labelled sense oligonucleotide primer, 10 pmol of antisense oligonucleotide primer, and 10 nmol of each deoxyribonucleotide triphosphate. One unit of Thermus aquaticus DNA polymerase (Perkin Elmer Cetus, Norwalk, CT, USA) was added and 100 μl of mineral oil layered over the samples. Samples were then incubated at 95°C, at annealing temperature (57°C for MLS1 and 60°C for GS4 and MS), and at 72°C for 45, 50, and 50 seconds respectively; this cycle was performed 36 times in a DNA-RNA amplifer (Biorad, Violet, Rome, Italy).

The products of the polymerase chain reaction were loaded on denaturing 6% polyacrylamide gels, which were analysed by autoradiography after electrophoresis.

Pairwise lod scores were calculated with the Mlink program from the LINKAGE package version 5.1-14 between the markers and between the disease locus and the extended GS4-MS-MLS1 haplotype. A gene frequency of 0.006 was used.

**Results**

Eight patients with late onset Friedreich’s disease were male and 14 were female (χ² = 1-41, NS). The patients were from 17 families, 12 from southern, three from northern, and two from central Italy. In two marriages parents were first cousins. A further seven affected siblings were not included in the study: four had onset before the age of 20 (at 4, 5, 6, and 18 years), two were dead, and one was not available for examination. The segregation ratio, calculated according to Weinberg’s “proband method”, was 0.33 (95% confidence interval 0.18–0.47). Mean age of onset (SD) was 25.8 (4.2) (range 21–36) years, mean age at last observation was 38.9 (7.8) (range 25–52) years, and mean duration of disease was 13.1 (8.2) (range 1–26) years. Eleven of our patients developed the disease after the age of 25 and two after the age of 30. Eleven patients reproduced and had a total of 26 children.

The most frequent presenting symptom was gait ataxia (91%), followed by lower limb weakness (9%). Table 1 shows the percentage occurrence of clinical and laboratory findings in patients with late onset Friedreich’s disease. Ten patients were in IAPS stage 2 (mean age (SD) 36.5 (8.4) years), six in IAPS stage 3 (38.8 (7.1) years), and six in IAPS stage 4 (43.2 (6.7) years). They were compared with 22 “typical” patients with Friedreich’s disease matched by sex and IAPS stage. Their mean age at onset was 11.4 (4.1) (range 1–19) years and disease duration 11.8 (8.5) (range 1–30) years. The only significant difference was a lower occurrence of skeletal deformities in late onset Friedreich’s disease.

Peripheral nerve motor and sensory conduction studies were abnormal in all 16 patients with late onset Friedreich’s disease examined and indicated a severe mainly sensory axonal degenerative neuropathy. Sural nerve biopsy in eight patients confirmed the loss of large myelinated fibres, which was pronounced in five, with unimodal distribution of axon diameters. Motor and somatosensory evoked potentials were abnormal in the five investigated patients. Brainstem auditory evoked potentials were abnormal in five out of nine patients and visual evoked potentials were normal in all six evaluated patients.

CT showed vermician atrophy in one out of 10 patients. MRI (T-1 field strength, Magnetom, Siemens AG, Germany) performed in five patients was abnormal in four, showing shrinkage of the cervical cord in all and atrophy of the vermis in two.

Disease progression through the IAPS version 5.1-14 was evaluated when personally observed or reliably referred. Ten patients reached IAPS stage 3 (loss of independent walking) after 10.2 (3.1) (range 4–17) years from the onset by the age of 34.9 (5.3) (range 25–44) and five patients reached IAPS stage 4 (wheelchair bound) after 17.2 (6.5) (12–27) years by the age of 40.6 (5.4) (range 35–49). The interval from onset to IAPS stage 3 was 8.2 (3.7) years in 50 patients with Friedreich’s disease and that from onset to IAPS stage 4 was 12.1 (4.7) years in 39. The last interval was significantly different between late onset Friedreich’s disease and Friedreich’s disease (Wilcoxon rank sum test, p = 0.04).

Linkage analysis was performed for 16 patients and 25 healthy members from eight families. The homogeneity test, by HOMOGEN program (version 3.3), showed no heterogeneity. No recombination was found between markers. Table 2 shows the results of linkage analysis between the extended MLS1-MS-GS4 haplotype and the disease locus. The peak lod score value was 5.17 at a recombination fraction θ = 0.00, showing the absence of any recombination event.

The frequency of the alleles of the various markers used was comparable with that found in “typical” patients with Friedreich’s disease and the normal population. No common MLS1-MS-GS4 haplotype was found in late onset Friedreich’s disease families (data not shown).
Late onset Friedreich's disease: clinical features and mapping of mutation to the FRDA locus

Table 2  Pairwise lod scores between late onset Friedreich’s disease locus and extended MLS1-MS-GS4 haplotype

<table>
<thead>
<tr>
<th>Family</th>
<th>0.00</th>
<th>0.05</th>
<th>0.10</th>
<th>0.20</th>
<th>0.30</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>-1.05</td>
<td>0.91</td>
<td>0.77</td>
<td>0.49</td>
<td>0.25</td>
</tr>
<tr>
<td>B</td>
<td>0.96</td>
<td>0.84</td>
<td>0.73</td>
<td>0.48</td>
<td>0.25</td>
</tr>
<tr>
<td>C</td>
<td>1.45</td>
<td>1.32</td>
<td>1.17</td>
<td>0.85</td>
<td>0.49</td>
</tr>
<tr>
<td>D</td>
<td>0.60</td>
<td>0.51</td>
<td>0.43</td>
<td>0.27</td>
<td>0.13</td>
</tr>
<tr>
<td>E</td>
<td>0.60</td>
<td>0.51</td>
<td>0.43</td>
<td>0.27</td>
<td>0.13</td>
</tr>
<tr>
<td>F</td>
<td>0.25</td>
<td>0.17</td>
<td>0.10</td>
<td>0.02</td>
<td>0.00</td>
</tr>
<tr>
<td>G</td>
<td>0.12</td>
<td>0.12</td>
<td>0.11</td>
<td>0.08</td>
<td>0.04</td>
</tr>
<tr>
<td>H</td>
<td>0.12</td>
<td>0.09</td>
<td>0.06</td>
<td>0.02</td>
<td>0.00</td>
</tr>
<tr>
<td>Total</td>
<td>5.17</td>
<td>4.84</td>
<td>3.80</td>
<td>2.48</td>
<td>1.29</td>
</tr>
</tbody>
</table>

*The pedigree of family A has been published.*

Discussion

We found an age of onset older than 20 in 19 out of 114 patients (17%) with a Friedreich’s disease phenotype. A comparison of their clinical and laboratory findings with those of patients with Friedreich’s disease of typical age of onset showed only a lower occurrence of pes cavus and scoliosis. This finding may be explained by an onset after full skeletal development. The occurrence of echocardiographic abnormalities was similar in patients with late onset Friedreich’s disease (14%) and matched patients with Friedreich’s disease (18%), but lower than that found in our study on a population of 50 patients with Friedreich’s disease (34%). The occurrence of abnormalities on CT was lower but not significantly in patients with late onset Friedreich’s disease. The neuropathological and morphological study of the peripheral nerve did not differentiate late onset Friedreich’s disease from Friedreich’s disease. The occurrence of abnormal motor and somatosensory evoked potentials and brain auditory evoked potentials was similar to that reported in Friedreich’s disease. Visually evoked potentials were always normal in late onset Friedreich’s disease, whereas they were abnormal in 69% of “typical” patients with Friedreich’s disease.

Disease progression, as indicated by years from onset to becoming confined to a wheelchair, was slower in patients with late onset Friedreich’s disease. Late onset Friedreich’s disease seems to be less severe than “typical” Friedreich’s disease, not only because of a later onset, but also because of a milder course. Many of our patients are still ambulant without support at advanced ages (up to 52 years), and many married and had children. The finding that a later onset could determine a slower progression may be relevant from a prognostic point of view.

Previous data suggested that late onset Friedreich’s disease might be due to secondary modifying genes acting on FRDA or to a different mutation. The mapping of the FRDA gene on chromosome 9 allowed a molecular genetic analysis in patients with late onset Friedreich’s disease to test locus heterogeneity. Our results clearly showed that Friedreich’s disease and late onset Friedreich’s disease map to the same locus.

Our study cannot answer the question whether the same mutation causes Friedreich’s disease and late onset Friedreich’s disease or if these diseases are caused by two or more allelic mutations. The coexistence of patients with onset before and after 20 years of age in some families shows that the same genetic defect can cause both Friedreich’s disease and late dominant Friedreich’s disease. Environmental factors or secondary modifying genes might account for the differences in age onset and progression. A different allelic mutation may, however, still be present in the families where all the affected have a late onset. The absence of a common haplotype in patients with late onset Friedreich’s disease suggests that, in any case, there is not a common “late onset” mutation in these pedigrees.

Strict diagnostic criteria were required for the molecular genetic studies that led to the FRDA mapping. Gene identification will probably expand the Friedreich’s disease phenotype proving also that some atypical cases may be caused by the same mutation. We believe, however, that age of onset before 20 years should not be considered an essential diagnostic criterion. Late onset is possible in Friedreich’s disease and it occurs in a substantial number of patients; the clinical picture is not distinguishable from that of early onset cases, but the progression of the disease is slower.

This study was partially supported by grants from CNR (No 91-04180) and from Italian Telethon (to MP).